MoFo News Item

MoFo Advises Catalyst on its Merger With Targacept

06 Mar 2015

MoFo is advising Catalyst Biosciences, Inc., a privately held biopharmaceutical company, on its merger with Targacept, Inc. The combined entity, to be named Catalyst Biosciences, Inc., is expected to create a financially strong company to harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.

The MoFo deal team was led by Northern Virginia and Palo Alto corporate partner Stephen Thau and New York partner Spencer Klein, with Northern Virginia corporate of counsel Daniel Max and associates Julien Bowers and Alejandra Fuster; Palo Alto corporate associates Jacqueline Tam and Shannon Sibold; San Francisco corporate associate Alfredo Silva; and New York benefits and compensation partner Domnick Bozzetti; and New York tax partner Remmelt Reigersman and associates Matthew Shiels and David Goett.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.